Provided By GlobeNewswire
Last update: Jan 16, 2025
TORONTO, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce that Avicanna has entered into a scientific and medical affairs collaboration agreement with Vectura Fertin Pharma.
Read more at globenewswire.com